CO6230993A2 - Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular - Google Patents

Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular

Info

Publication number
CO6230993A2
CO6230993A2 CO09103873A CO09103873A CO6230993A2 CO 6230993 A2 CO6230993 A2 CO 6230993A2 CO 09103873 A CO09103873 A CO 09103873A CO 09103873 A CO09103873 A CO 09103873A CO 6230993 A2 CO6230993 A2 CO 6230993A2
Authority
CO
Colombia
Prior art keywords
copper
copper salt
coated
masked
use according
Prior art date
Application number
CO09103873A
Other languages
English (en)
Inventor
George Ludwig Kis
Jacques Vandermander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6230993(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6230993A2 publication Critical patent/CO6230993A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

1.- El uso de una sal de cobre enmascarada o recubierta en una composición farmacéutica para el tratamiento y/o la prevención de una enfermedad que se pueda tratar y/o prevenir mediante una sal de cobre. 2.- El uso de la reivindicación 1, en donde la enfermedad mencionada es degeneración macular relacionada con la edad o retinopatía diabética. 3.- El uso de una sal de cobre enmascarada o recubierta en un método para estabilizar una composición farmacéutica a partir de la descomposición dependiente de la sal de cobre. 4.- El uso de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la composición farmacéutica mencionada comprende uno o más compuestos sensibles al cobre, tales como un ácido graso Omega-3, vitamina C, vitamina E, luteína y/o zeaxantina. 5.- El uso de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el cobre mencionado se recubre con gelatina, un liposoma, o un mono- y di-glicérido. 6.- El uso de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el cobre mencionado es gluconato de cobre, óxido de cobre, carbonato de cobre, o cloruro de cobre. 7.- El uso de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el recubrimiento mencionado es un fosfolípido zwiteriónico, incluyendo, pero no limitándose a, fosfatidil-colina, fosfatidil-serina, fosfatidil-etanolamina, esfingomielina y otras cerámicas, así como otros diferentes fosfolípidos zwiteriónicos. 8.- El uso de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el cobre mencionado es un complejo de cobre-ciclodextrina. 9.- Un material de cápsula digestible, en particular un material de cápsula digestible en el tracto gastrointestinal, el cual contiene una sal de cobre enmascarada y/o recubierta, caracterizado porque este material de cápsula representa el material de enmascaramiento y/o recubrimiento para la sal de cobre. 10.- Un material de cápsula digestible de la reivindicación 9, en donde la sal de cobre mencionada ya está recubierta con un recubrimiento, y este recubrimiento podría ser el mismo u otro material de enmascaramiento diferente del material de cápsula mencionado.
CO09103873A 2007-03-23 2009-09-23 Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular CO6230993A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104792A EP1974733A1 (en) 2007-03-23 2007-03-23 Use of a masked or coated copper salt for the treatment of macular degeneration
EP07111322 2007-06-28

Publications (1)

Publication Number Publication Date
CO6230993A2 true CO6230993A2 (es) 2010-12-20

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09103873A CO6230993A2 (es) 2007-03-23 2009-09-23 Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular

Country Status (26)

Country Link
US (1) US20080233182A1 (es)
EP (1) EP2124973B1 (es)
JP (1) JP2010521534A (es)
KR (1) KR101688656B1 (es)
AR (1) AR065791A1 (es)
AU (1) AU2008231847B2 (es)
BR (1) BRPI0809258B8 (es)
CA (1) CA2681514C (es)
CL (1) CL2008000804A1 (es)
CO (1) CO6230993A2 (es)
DK (1) DK2124973T3 (es)
EC (1) ECSP099700A (es)
ES (1) ES2542694T3 (es)
GT (1) GT200900251A (es)
IL (1) IL201109A (es)
MA (1) MA31293B1 (es)
MX (1) MX2009010244A (es)
MY (1) MY164520A (es)
NZ (1) NZ579852A (es)
PE (1) PE20090186A1 (es)
PL (1) PL2124973T3 (es)
PT (1) PT2124973E (es)
RU (1) RU2009139002A (es)
TN (1) TN2009000387A1 (es)
TW (1) TW200904456A (es)
WO (1) WO2008116806A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595204A (en) 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (es) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
WO2005110375A1 (en) * 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
AU2005271897B2 (en) * 2004-07-09 2008-06-19 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
US7884131B2 (en) * 2004-11-19 2011-02-08 Martek Biosciences, Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Also Published As

Publication number Publication date
TW200904456A (en) 2009-02-01
DK2124973T3 (da) 2015-06-22
ES2542694T3 (es) 2015-08-10
TN2009000387A1 (en) 2010-12-31
PL2124973T3 (pl) 2015-10-30
IL201109A (en) 2016-10-31
EP2124973B1 (en) 2015-05-27
GT200900251A (es) 2018-10-08
BRPI0809258B8 (pt) 2021-05-25
PE20090186A1 (es) 2009-03-20
US20080233182A1 (en) 2008-09-25
EP2124973A1 (en) 2009-12-02
AR065791A1 (es) 2009-07-01
RU2009139002A (ru) 2011-04-27
PT2124973E (pt) 2015-09-01
AU2008231847B2 (en) 2012-12-06
WO2008116806A1 (en) 2008-10-02
MA31293B1 (fr) 2010-04-01
KR101688656B1 (ko) 2016-12-21
BRPI0809258A2 (pt) 2014-09-23
CA2681514A1 (en) 2008-10-02
MX2009010244A (es) 2009-10-26
KR20100015799A (ko) 2010-02-12
CA2681514C (en) 2016-11-08
MY164520A (en) 2017-12-29
JP2010521534A (ja) 2010-06-24
AU2008231847A1 (en) 2008-10-02
BRPI0809258B1 (pt) 2019-10-01
IL201109A0 (en) 2010-05-17
NZ579852A (en) 2012-03-30
CL2008000804A1 (es) 2008-10-24
ECSP099700A (es) 2009-11-30

Similar Documents

Publication Publication Date Title
van Wijk et al. Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination
Bazan Homeostatic regulation of photoreceptor cell integrity: Significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid the proctor lecture
Rocha et al. Intragastric nitration by dietary nitrite: implications for modulation of protein and lipid signaling
PE20081580A1 (es) Composicion suplementaria nutricional para el tratamiento enfermedades oculares
DE202011050351U1 (de) Diätetische Erzeugnisse bzw. Formulierungen
EP1861109A2 (en) Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
RU2009126740A (ru) Композиция питательной добавки, предназначенная для лечения глазных болезней
Barcelos et al. Effects of ω-3 essential fatty acids (ω-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter
Watson et al. Redox agents modulate neuronal activity and reproduce physiological aspects of neuronal aging
Matsushita et al. Antioxidant activity of polar carotenoids including astaxanthin-β-glucoside from marine bacterium on PC liposomes
WO2008024020A1 (en) Liposomal composition of antioxidants for inhalations carried out during lung and upper respiratory tract diseases
CO6230993A2 (es) Uso de una sal de cobre enmascarada o recubierta para el tratamiento de degeneracion macular
US20200261488A1 (en) Method for treating traumatic brain injury
CA2599468A1 (en) Vitamin mixtures
Perri et al. Proliferative and anti-proliferative effects of retinoic acid at doses similar to endogenous levels in Leydig MLTC-1/R2C/TM-3 cells
Wang et al. The bioactive of four dietary sources phospholipids on heavy metal-induced skeletal muscle injury in zebrafish: A comparison of phospholipid profiles
US20070009590A1 (en) Physiologically active composition based on phosphatidylserine
AR070405A1 (es) Composiciones para la prevencion y/o el tratamiento de la degeneracion macular y/o la perdida de la agudeza visual
Chatgilialoglu et al. Biomimetic chemistry: radical reactions in vesicle suspensions
JP2010521534A5 (es)
Białek et al. Evaluation of the influence of diet supplementation with conjugated linoleic acid isomers on elemental composition in the cardio-oncological nutritional programming rat’model
Joshi et al. Docosahexaenoic acid reverses aluminium induced alteration in vitamins and lipid profiles in rat serum
UA144000U (uk) ПРЕПАРАТ ЛІПОСОМАЛЬНОГО <font face="Symbol">b</font>-КАРОТИНУ ДЛЯ ЛІКУВАННЯ І ПРОФІЛАКТИКИ ГІПОВІТАМІНОЗУ А
Sijben et al. Synaptic membrane synthesis in rats depends on dietary sufficiency of vitamin C, vitamin E, and selenium: Relevance for alzheimer's disease
EP1974733A1 (en) Use of a masked or coated copper salt for the treatment of macular degeneration

Legal Events

Date Code Title Description
FC Application refused